Treatment with β-blockers -: the value of an even plasma concentration over 24 h

被引:10
作者
Agewall, S [1 ]
Kendall, M
机构
[1] Gothenburg Univ, Sahlgrens Univ Hosp, Dept Internal Med, S-41345 Gothenburg, Sweden
[2] Univ Birmingham, Sch Med, Dept Pharmacol, Birmingham, W Midlands, England
关键词
D O I
10.1046/j.1365-2710.1997.8775087.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this paper was to examine if there were clinical studies supporting a beneficial effect of an even plasma concentration over 24 h for the most frequently prescribed beta 1-blockers in clinical practice, metoprolol CR/ZOK and atenolol. There are several studies showing that metoprolol CR/ZOK has a more even plasma concentration compared with atenolol and conventional metoprolol tablets when administered once daily. There are also studies showing that metoprolol CR/ZOK produces a more even beta 1-blockade over 24 h. This is determined by expressing the percentage reduction in exercise heart rate in relation to placebo at intervals throughout the 24-h period and comparing the results with those of atenolol and conventional metoprolol tablets. Clinical studies indicate that the low peak plasma concentration produced by metoprolol CR/ZOK leads to more beta 1 selectivity than atenolol and conventional metoprolol tablets. The loss of beta 1 selectivity at peak plasma concentrations may cause unwanted side-effects. The peak plasma concentration of atenolol coincides with increased general and leg fatigue, problems less evident when patients are on metoprolol CR/ZOK. The frequency and severity of other central nervous system related side-effects are comparable with metoprolol CR/ZOK and atenolol. In conclusion, there are several clinical studies supporting a beneficial effect of the even plasma concentration over 24 h achieved with metoprolol CR/ZOK.
引用
收藏
页码:171 / 179
页数:9
相关论文
共 41 条
[1]   THE EFFICACY OF MULTIPLE RISK FACTOR INTERVENTION IN TREATED HYPERTENSIVE MEN DURING LONG-TERM FOLLOW-UP [J].
AGEWALL, S ;
WIKSTRAND, J ;
SAMUELSSON, O ;
PERSSON, B ;
ANDERSSON, OK ;
FAGERBERG, B .
JOURNAL OF INTERNAL MEDICINE, 1994, 236 (06) :651-659
[2]   PHARMACOKINETICS AND PHARMACODYNAMICS OF CONTROLLED-RELEASE METOPROLOL - A COMPARISON WITH ATENOLOL [J].
BLOMQVIST, I ;
WESTERGREN, G ;
SANDBERG, A ;
JONSSON, UE ;
LUNDBORG, P .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 33 :S19-S24
[3]  
Dahlof C, 1988, Ann Clin Res, V20 Suppl 48, P42
[4]   PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF CONTROLLED RELEASE (CR ZOK) METOPROLOL IN HEALTHY ORIENTAL SUBJECTS - A COMPARISON WITH CONVENTIONAL FORMULATIONS OF METOPROLOL AND ATENOLOL [J].
DARMANSJAH, I ;
WONG, E ;
SETIAWATI, A ;
MOELOEK, D ;
IRAWATI, D ;
SIAGIAN, M ;
MUCHTAR, A .
JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (02) :S39-S45
[5]   TOLERABILITY AND WELL-BEING WITH METOPROLOL IN A CONTROLLED RELEASE (CR ZOK) FORMULATION - A REVIEW ARTICLE [J].
DIMENAS, E ;
DAHLOF, C .
JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (02) :S92-S97
[6]   BETA-ADRENOCEPTOR BLOCKADE AND CNS-RELATED SUBJECTIVE SYMPTOMS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED COMPARISON OF METOPROLOL CR ZOK, ATENOLOL AND PROPRANOLOL LA IN HEALTHY-SUBJECTS [J].
DIMENAS, E ;
KERR, D ;
MACDONALD, I .
JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (02) :S103-S107
[7]  
DIMENAS E, 1960, EUROPEAN J CLIN PHAR, V38, P571
[8]   THE ANTIANGINAL EFFICACY AND TOLERABILITY OF CONTROLLED-RELEASE METOPROLOL ONCE DAILY - A COMPARISON WITH CONVENTIONAL METOPROLOL TABLETS TWICE DAILY [J].
EGSTRUP, K ;
GUNDERSEN, T ;
HARKONEN, R ;
KARLSSON, E ;
LUNDGREN, B .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 33 :S45-S45
[9]  
FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707
[10]   THE EFFECT OF BETA-BLOCKERS ON MENTAL PERFORMANCE ON OLDER HYPERTENSIVE PATIENTS [J].
GENGO, FM ;
FAGAN, SC ;
DEPADOVA, A ;
MILLER, JK ;
KINKEL, PR .
ARCHIVES OF INTERNAL MEDICINE, 1988, 148 (04) :779-784